Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-Of-Concept Clinical Trial

Clinical Pharmacology and Therapeutics - United States
doi 10.1038/clpt.2011.370
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Proof of Concept to Clinical Confirmation: Evolving Clinical Trial Designs for Targeted Agents

ISRN Oncology
2012English

Discovery of Hypocretin/Orexin Ushers in a New Era of Sleep Research

Trends in Neurosciences
Neuroscience
2018English

A Selective Neurokinin-1 Receptor Antagonist in Chronic PTSD: A Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial

European Neuropsychopharmacology
PsychiatryMental HealthNeurologyBiological PsychiatryPharmacology
2011English

DOA: A New Paradigm of the Level of Proof or a Simple Complementary Tool?

European Journal of Vascular and Endovascular Surgery
SurgeryCardiovascular MedicineCardiology
2019English

Towards a New Code-Based Software Development Concept Enabling Code Patterns

2007English

Cardiac Output-Based Fluid Optimization for Kidney Transplant Recipients: A Proof-Of-Concept Trial

Canadian Journal of Anaesthesia
MedicineAnesthesiologyPain Medicine
2018English

A New Paradigm for Clinical Trials in Antibiotherapy?

Canadian Journal of Infectious Diseases and Medical Microbiology
Infectious DiseasesMicrobiology
2011English

Preliminary Immunohistochemical Results on a New Implant Surface: A Proof-Of-Concept Randomized Study

Clinical Oral Implants Research
Oral Surgery
2017English

Orexin/Hypocretin-1 Receptor Antagonism Reduces Ethanol Self-Administration and Reinstatement Selectively in Highly-Motivated Rats

Brain Research
NeuroscienceNeurologyDevelopmental BiologyMolecular Biology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy